Unknown

Dataset Information

0

Inflammatory Cytokine: IL-17A Signaling Pathway in Patients Present with COVID-19 and Current Treatment Strategy.


ABSTRACT: Coronavirus disease 2019 (COVID-19) is a globally communicable public health disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Eradication of COVID-19 appears practically impossible but, therefore, more effective pharmacotherapy is needed. The deteriorated clinical presentation of patients with COVID-19 is mainly associated with hypercytokinemia due to notoriously elevated pro-inflammatory cytokines such as interleukin (IL)-1B, IL-6, IL-8, IL-17, granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF), interferon-?-inducible protein (IP10), monocyte chemoattractant protein (MCP1), and tumor necrosis factor-? (TNF?), and is usually responsible for cytokine release syndrome. In the cytokine storm, up-regulation of T-helper 17 cell cytokine IL-17A, and maybe also IL-17F, is mostly responsible for the immunopathology of COVID-19 and acute respiratory distress syndrome. Herein, I meticulously review the exuberant polarization mechanism of naïve CD4+ T cells toward Th17 cells in response to SARS-CoV-2 infection and its associated immunopathological sequelae. I also, propose, for clinical benefit, targeting IL-17A signaling and the synergic inflammatory cytokine IL-6 to manage COVID-19 patients, particularly those presenting with cytokine storm syndrome.

SUBMITTER: Shibabaw T 

PROVIDER: S-EPMC7547786 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

altmetric image

Publications

Inflammatory Cytokine: IL-17A Signaling Pathway in Patients Present with COVID-19 and Current Treatment Strategy.

Shibabaw Tewodros T  

Journal of inflammation research 20201006


Coronavirus disease 2019 (COVID-19) is a globally communicable public health disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Eradication of COVID-19 appears practically impossible but, therefore, more effective pharmacotherapy is needed. The deteriorated clinical presentation of patients with COVID-19 is mainly associated with hypercytokinemia due to notoriously elevated pro-inflammatory cytokines such as interleukin (IL)-1B, IL-6, IL-8, IL-17, granulocyte-macroph  ...[more]

Similar Datasets

| S-EPMC9147816 | biostudies-literature
| S-EPMC3871633 | biostudies-literature
| S-EPMC10754973 | biostudies-literature
| S-EPMC4602333 | biostudies-literature
2012-01-31 | E-GEOD-31652 | biostudies-arrayexpress
| S-EPMC11282404 | biostudies-literature
| S-EPMC9342424 | biostudies-literature
| S-EPMC8044579 | biostudies-literature
| S-EPMC5077677 | biostudies-literature
| S-EPMC3316904 | biostudies-literature